Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C

NCT03500562 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT03500562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03500562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Terminated
Start date
May 8, 2018
Completion date
March 29, 2019
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c